Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618332 · ClinicalTrials.gov registry record · NA
Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
A NA study, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00618332 is a NA study that has completed, run by University of Chicago. The registered enrollment target is 40 participants.
The verdict
NCT00618332, a NA study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prior studies.
Interventions
- DRUG placebo
- DRUG mometasone furoate nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618332
The ClinicalTrials.gov registry entry for NCT00618332 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00618332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618332 about?
NCT00618332 is a clinical study titled "Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?". We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% r...
What is the current status of trial NCT00618332?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2008-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00618332?
The interventions under investigation include: placebo (DRUG), mometasone furoate nasal spray (DRUG).
Who is sponsoring clinical trial NCT00618332?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.